The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes

Leukemia Research

Volumn 31, Issue 1, 2007, Pages 11-17

  Silver, R T ^a   Bennett, J M ^b   Goldman, J M ^c   Spivak, J L ^d   Tefferi, A ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mayo Clinic   (United States)

Author keywords

JAK2; Leukemia; Myelodysplastic syndrome; Myeloproliferative

Indexed keywords

4 METHYL N [3 (4 METHYL 1 IMIDAZOLYL) 5 (TRIFLUOROMETHYL)PHENYL] 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CORTICOSTEROID; CYTARABINE; DANAZOL; DNA TOPOISOMERASE INHIBITOR; ERYTHROPOIETIN; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; LONAFARNIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIRFENIDONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SURAMIN; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VATALANIB;

ARTICLE; BONE MARROW CELL; CANCER CENTER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; GENE MUTATION; HUMAN; LIFE EVENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTOPENIA; UNITED STATES;

HUMANS; LEUKEMIA, MYELOID, CHRONIC; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS;

EID: 33750730622     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.02.023     Document Type: Article

References (0)